EUVIMEDEUVIMED entdecken
Crossref

Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway

Heba A Bahriz, Rania R Abdelaziz, Dalia H El-Kashef

Toxicology and Applied Pharmacology · 2025

DOI: 10.1016/j.taap.2024.117202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicology and Applied Pharmacology, 2025. Verfasst von Heba A Bahriz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Myeloid Differentiation Factor 88, Loratadine, NF-kappa B. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Mansoura University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapeutic medication-induced systemic toxicity makes cancer treatment less effective. Thus, the need for drug repurposing, which aids in the development of safe and efficient cancer therapies, is urgent. The primary goal of this research was to assess desloratadine hepatoprotective abilities and its capacity to attenuate TLR4/MyD88/NF-κB inflammatory pathway in hepatocellular carcinoma (HCC) induced by thioacetamide (TAA). Male Sprague Dawely rats received TAA injections (200 mg/kg, i.p., 2 times/week) for 16 weeks. To confirm the development of HCC, liver function biomarkers and histopathological analysis were evaluated. Desloratadine (5 mg/kg, p.o.) was administered to rats in 2 treatment groups; HCC + DES 1 group received desloratadine with TAA for 1 month from week 13-16, HCC + DES 2 group received desloratadine with TAA for 2 months from week 9-16. Chronic TAA administration resulted in considerable overexpression of the profibrogenic cytokine TGF-β and elevation in protein expression of NF-κB besides levels of TLR4, MyD88, TRAF6, TAK1 and IL-1β. Desloratadine administration showed a significant improvement in liver function tests, as well as an increase in tissue antioxidant enzymes and an improvement in the liver's histopathological features. Collectively, desloratadine through modulating TLR4/MyD88/TRAF6/TAK1/NF-κB and acting as an antioxidant, is a promising treatment for HCC induced by TAA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 4Myeloid Differentiation Factor 88LoratadineNF-kappa BCarcinoma, HepatocellularLiver NeoplasmsLiver Neoplasms, ExperimentalAnimalsMaleRats, Sprague-DawleySignal TransductionRatsThioacetamideLiver

Stichwörter der Autor:innen

DesloratadineHepatocellular carcinomaTLR4/MYD88/NF-κBThioacetamide

Substanzen

Toll-Like Receptor 4Myeloid Differentiation Factor 88LoratadineNF-kappa BTlr4 protein, ratdesloratadineMyd88 protein, ratThioacetamide

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Electronic address: rania200582@yahoo.com.

Förderung

  • Mansoura University

Zitieren

APA

Bahriz, H. A., Abdelaziz, R. R., & El-Kashef, D. H. (2025). Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2024.117202

Vancouver

Bahriz HA, Abdelaziz RR, El-Kashef DH. Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway. Toxicology and Applied Pharmacology. 2025. doi:10.1016/j.taap.2024.117202

BibTeX
@article{Bahriz2025,
  author = {Bahriz, Heba A and Abdelaziz, Rania R and El-Kashef, Dalia H},
  title = {Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway},
  journal = {Toxicology and Applied Pharmacology},
  year = {2025},
  doi = {10.1016/j.taap.2024.117202}
}
Kostenlos starten →